Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results
Sotera Health Co (SHC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results • Q3 2026 net revenues increased 4.4% on both an as-reported and constant currency basis (1) , compared to Q3 2025 • Q3 2026 net income of $58 million or $0.20 per diluted share • Q3 2026 Adjuste
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The reaffirmed guidance signals continuity in growth and margin expansion, which may sustain current valuation levels.
Market read
Earnings release with reaffirmed guidance provides modest trading relevance for SHC, primarily for short‑term positioning.
What to watch
The decline in Nordion revenue due to Co‑60 harvest timing could weigh on segment margins if the issue persists.
Sotera Health Reports Solid Third-Quarter and Year-to-Date 2026 Results
Third-quarter net revenues increased 4.4%, Adjusted EBITDA increased 3.9%, and Adjusted EPS increased 12% per diluted share. Sterigenics and Nelson Labs posted constant currency growth, while expected Co-60 harvest timing drove an 11.5% constant currency revenue decline at Nordion.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Q3 2026 service revenuesGAAP | $277.1M | – | – |
| Q3 2026 product revenuesGAAP | $47.79M | – | – |
| Q3 2026 total net revenuesGAAP | $324.9M | – | 4.4% |
| Q3 2026 total net revenues constant currency growthnon-GAAP | 4.4% | – | 4.4% |
| Q3 2026 service cost of revenuesGAAP | $127.1M | – | – |
| Q3 2026 product cost of revenuesGAAP | $17.00M | – | – |
| Q3 2026 total cost of revenuesGAAP | $144.1M | – | – |
| Q3 2026 gross profitGAAP | $180.8M | – | – |
| Q3 2026 selling, general and administrative expensesGAAP | $64.14M | – | – |
| Q3 2026 amortization of intangible assetsGAAP | $3.00M | – | – |
| Q3 2026 interest expense, netGAAP | $34.12M | – | – |
| Q3 2026 loss on refinancing of debtGAAP | — | – | – |
| Q3 2026 foreign exchange gain, netGAAP | −$1.09M | – | – |
| Q3 2026 other income, netGAAP | −$3.11M | – | – |
| Q3 2026 income before income taxesGAAP | $83.73M | – | – |
| Q3 2026 provision for income taxesGAAP | $25.34M | – | – |
| Q3 2026 net incomeGAAP | $58.39M | – | – |
| Q3 2026 diluted earnings per shareGAAP | $ 0.20 | – | – |
| Q3 2026 Adjusted Net Incomenon-GAAP | $82.49M | – | – |
| Q3 2026 Adjusted EBITDAnon-GAAP | $170.7M | – | 3.9% |
| Q3 2026 Adjusted EBITDA constant currency growthnon-GAAP | 4.0% | – | 4.0% |
| Q3 2026 Adjusted EBITDA marginnon-GAAP | 52.5 % | improved nearly 100 basis points | – |
| Q3 2026 adjusted diluted earnings per sharenon-GAAP | $ 0.29 | – | 12% |
| Nine months 2026 total net revenuesGAAP | $926.3M | – | – |
| Nine months 2026 gross profitGAAP | $505.8M | – | – |
| Nine months 2026 net incomeGAAP | $138.6M | – | – |
| Nine months 2026 diluted earnings per shareGAAP | $ 0.48 | – | – |
| Nine months 2026 Adjusted EBITDAnon-GAAP | $471.1M | – | – |
| Nine months 2026 Adjusted EBITDA marginnon-GAAP | 50.9 % | – | – |
| Nine months 2026 adjusted diluted earnings per sharenon-GAAP | $ 0.72 | – | – |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Sterigenics Q3 2026Net revenues growth was driven by pricing, improved volume and mix, and a foreign currency benefit. | $209M | – | 8.5% |
| Nordion Q3 2026Unfavorable volume and mix due to the expected timing of Co-60 harvest schedules and foreign exchange were partially offset by favorable pricing. | $55M | – | decrease of 12.4% |
| Nelson Labs Q3 2026Net revenues and segment income growth were driven by favorable volume and mix as well as pricing, partially offset by foreign exchange. | $61M | – | 8.8% |
| Sterigenics nine months 2026Segment income increased 9.6% to $332 million. | $607M | – | 8.9% |
| Nordion nine months 2026Segment income increased 8.2% to $85 million. | $146M | – | 6.1% |
| Nelson Labs nine months 2026Segment income decreased 2.4% to $54 million. | $173M | – | 4.9% |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Full-Year 2026 Outlook outlook
- RevenueNet revenues in the range of $1.233 billion to $1.250 billion, representing constant currency growth of 5.25% to 6.75%.
- Tax rateTax rate applicable to Adjusted Net Income remains in the range of 27.0% to 28.0%.
- NoteAdjusted EBITDA in the range of $632 million to $641 million, representing constant currency growth of 5.75% to 7.25%.
- NoteFull-year Adjusted EBITDA margins approximately flat versus 2025.
- NoteThe foreign currency benefit to net revenues and Adjusted EBITDA has been revised to 70 basis points from 100 basis points in our previous outlook.
- NoteInterest expense narrowed to a range of $137 million to $140 million.
- NoteAdjusted EPS range remains in the range of $0.95 to $1.01.
- NoteA weighted-average fully diluted share count remains in the range of 289 million to 291 million shares.
- NoteCapital expenditures remain in the range of $200 million to $225 million.
What drove it
- Sterigenics delivered 8.2% constant currency revenue growth in the third quarter, supported by pricing, improved volume and mix.
- Nelson Labs delivered 9.2% constant currency revenue growth in the third quarter, supported by favorable volume and mix as well as pricing.
- Nordion third-quarter revenue was affected by expected Co-60 harvest timing, with unfavorable volume and mix and foreign exchange partially offset by favorable pricing.
- Nordion segment income margin improved due to operational productivity and favorable pricing, partially offset by inflation.
- A new Nelson Labs Annex-1 compliant cleanroom was completed during the quarter.
Concerns
- Nordion third-quarter constant currency revenue declined 11.5% due to expected Co-60 harvest timing.
- Nelson Labs third-quarter segment income increased 2.5%, while its segment income margin was impacted primarily by business mix.
- The foreign currency benefit to full-year net revenues and Adjusted EBITDA was revised to 70 basis points from 100 basis points.
- The outlook is based on expectations regarding supply chain continuity, particularly for the supply of ethylene oxide and Co-60, and the impact of inflationary trends.
- The company identifies litigation related to EO emissions and releases, leverage, regulatory requirements, material availability, inflation, and foreign currency exchange rates among its risks.
What to watch
- Full-year delivery against net revenue guidance of $1.233 billion to $1.250 billion and Adjusted EBITDA guidance of $632 million to $641 million.
- Nordion revenue progression as Co-60 harvest schedules affect volume and mix.
- Whether full-year Adjusted EBITDA margins are approximately flat versus 2025.
- Capital expenditures within the guided range of $200 million to $225 million.
- Net Leverage following the reported improvement to 2.9x and the Moody's Ratings credit rating upgrade in early October.
Balance sheet and cash flow
- As of September 30, 2026, total debt was $2.2 billion and unrestricted cash and cash equivalents were $412 million.
- Total Debt was $ 2,244,260 (in thousands) as of September 30, 2026, compared to $ 2,237,997 (in thousands) as of December 31, 2025.
- Cash and cash equivalents were $ 412,393 (in thousands) as of September 30, 2026, compared to $ 346,456 (in thousands) as of December 31, 2025.
- Net Debt was $ 1,831,876 (in thousands) as of September 30, 2026, compared to $ 1,893,376 (in thousands) as of December 31, 2025.
- Net Leverage was 2.9x as of September 30, 2026, compared to 3.2x as of December 31, 2025.
- Q3 2026 net cash provided by operating activities was $111 million.
- Nine months 2026 net cash provided by operating activities was $ 228,479 (in thousands), compared to $ 184,091 (in thousands).
- Nine months 2026 purchases of property, plant and equipment were $ (145,450) (in thousands), compared to $ (87,319) (in thousands).
- Nine months 2026 net cash used in investing activities was $ (140,175) (in thousands), compared to $ (84,445) (in thousands).
- Nine months 2026 payments on long-term borrowings were $ (7,097) (in thousands), compared to $ (82,547) (in thousands).
- Nine months 2026 net cash used in financing activities was $ (16,978) (in thousands), compared to $ (92,359) (in thousands).
Analysis
Sotera Health reported third-quarter 2026 total net revenues of $324,886 (in thousands), compared with $311,312 (in thousands) in the prior-year quarter, with the release describing 4.4% growth both as reported and on a constant currency basis. Net income was $58,391 (in thousands), compared with $48,400 (in thousands), while diluted earnings per share were $0.20 versus $0.17. Adjusted EBITDA was $170,665 (in thousands), compared with $164,190 (in thousands), and adjusted diluted earnings per share increased to $0.29 from $0.26.
Segment trends were uneven but favorable overall. Sterigenics generated $209 million of third-quarter revenue, up 8.5%, or 8.2% on a constant currency basis, with growth attributed to pricing, improved volume and mix, and a foreign currency benefit. Nelson Labs generated $61 million, up 8.8%, or 9.2% on a constant currency basis, driven by favorable volume and mix and pricing. Nordion generated $55 million, a decrease of 12.4%, or 11.5% on a constant currency basis, due to expected Co-60 harvest timing.
Profitability reflected contrasting segment dynamics. Third-quarter Adjusted EBITDA margin was 52.5 %, compared with 52.7 % in the prior-year quarter, while management said sequential Adjusted EBITDA margin improved nearly 100 basis points. Sterigenics segment income improved 9.6% to $117 million and Nordion segment income margin improved through operational productivity and favorable pricing, partly offset by inflation. Nelson Labs segment income increased 2.5% to $19 million, with its segment income margin impacted primarily by business mix.
Cash generation and leverage continued to improve. The company reported $111 million of net cash provided by operating activities in the quarter and $228,479 (in thousands) in the first nine months. Net Debt was $1,831,876 (in thousands) as of September 30, 2026, compared with $1,893,376 (in thousands) as of December 31, 2025, while Net Leverage improved to 2.9x from 3.2x. Capital investment remained significant, with nine-month purchases of property, plant and equipment of $145,450 (in thousands).
Management reaffirmed its full-year revenue and Adjusted EBITDA outlook, calling for net revenues of $1.233 billion to $1.250 billion and Adjusted EBITDA of $632 million to $641 million. The company narrowed expected interest expense to $137 million to $140 million, retained its $0.95 to $1.01 Adjusted EPS range, and retained capital expenditure guidance of $200 million to $225 million. The foreign currency benefit to revenue and Adjusted EBITDA was revised to 70 basis points from 100 basis points in the previous outlook.
Management, verbatim
We are pleased with our third-quarter performance, which included solid top- and bottom-line constant currency growth, along with nearly 100 basis points of sequential Adjusted EBITDA margin expansion.
Alton Shader, Chief Executive Officer
Based on our year-to-date performance and expectations for the remainder of the year, we are reaffirming our 2026 constant currency revenue and Adjusted EBITDA outlook.
Alton Shader, Chief Executive Officer
Not in the filing
stated, not guessed- GAAP operating income was not reported.
- GAAP gross margin was not reported.
- Free cash flow was not reported.
- Third-quarter capital expenditures were not reported.
- Share repurchases were not reported.
- Dividends were not reported.
- The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
The filing is an SEC Form 8‑K reporting Sotera Health's Q3 2026 financial results and reaffirming its full‑year outlook.
Ticker impact
Sotera Health reaffirmed its 2026 revenue and Adjusted EBITDA outlook in its Q3 2026 earnings release.
likely modest upside as investors view the reaffirmed outlook positively
The company posted solid Q3 results and confirmed its full‑year guidance, which typically limits downside risk and may attract buying on the back of steady growth.
Market effects
Sotera Health's steady guidance may reinforce confidence in the healthcare sterilization and lab‑testing sector.
Limited to U.S. and North American healthcare service markets.
Minimal global impact beyond sector peers.
Counterpoint
If investors expected a raise in guidance, the reaffirmation could be seen as a disappointment, potentially pressuring the stock.
Key entities
- companySotera Health Co.
Provider of sterilization, lab testing, and advisory services to the healthcare industry.



